PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Kurt W. Evans

The University of Texas MD Anderson Cancer Center

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 8, 2026 · JOURNAL ARTICLE

Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan

Jnci Journal of the National Cancer Institute

Preclinical mechanistic study in cell lines and xenografts proposing a combination strategy; no clinical trial data, no human efficacy endpoints, and no regulatory or phase 1+ evidence to support practice change.

Hypothesis-GeneratingBailiang Wang Erkan Yuca HER2/EGFR in Cancer Research

Reported

Study modelPatient-derived xenografts (PDXs) and cell…

ComparisonsSG + birinapant or tolinapant vs. SG alone

Primary outcome measureEvent-free survival in PDX; cell viability,…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support